You are totally on the money here stockrock. CHM have mentioned many times that if the results of this phase 1 trial are promising, the next trial (a phase 2b) would be potentially an approval trial. And because GBM is such an agressive cancer, with no SOC, the fast track approval pathway is likely. And because few patient make it past 6 months with GBM, the phase 2b wont be an overly long trial.
If/when GBM approval is granted, the company will be revenue generating, and able to progress the drug to other indications, without diluting the SOI.
Huge potential here.
CHM Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)